SRZNW
Surrozen Inc. WarrantKey Statistics
About Surrozen Inc. Warrant
Surrozen Inc. is an innovative biotechnology company focused on developing breakthrough therapeutics for complex diseases through its proprietary platform that emphasizes targeted biology. By specializing in antibody therapeutics with tissue-specific delivery mechanisms, Surrozen aims to precisely modulate key biological pathways implicated in various ailments. With a robust pipeline of drug candidates at differing stages of development, the company is poised to advance transformative solutions in regenerative medicine. Supported by a seasoned management team and strategic collaborations, Surrozen is strategically positioned to pioneer advancements in patient care and redefine treatment approaches in its sector.
Fundamentals
| Revenue (TTM) | $7.49M |
| Gross Profit (TTM) | $-24.64M |
| EBITDA | $-42.69M |
| Operating Margin | -209.10% |
| Return on Equity | -62.80% |
| Return on Assets | -22.80% |
| Revenue/Share (TTM) | $0.81 |
| Book Value | $-24.21 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 408.60% |
| Shares Outstanding | 0 |
| Float | $5.42M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SRZNW and any ticker you trade — then tracks every position and per-strategy win rate.